Logo image of ALMKS.PA

MAKING SCIENCE GROUP SA (ALMKS.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:ALMKS - ES0105463006 - Common Stock

8.15 EUR
-0.05 (-0.61%)
Last: 11/26/2025, 7:00:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ALMKS. ALMKS was compared to 70 industry peers in the Media industry. ALMKS has a bad profitability rating. Also its financial health evaluation is rather negative. ALMKS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

ALMKS had negative earnings in the past year.
In the past year ALMKS had a positive cash flow from operations.
In the past 5 years ALMKS reported 4 times negative net income.
ALMKS had a positive operating cash flow in 4 of the past 5 years.
ALMKS.PA Yearly Net Income VS EBIT VS OCF VS FCFALMKS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -1.00%, ALMKS is doing worse than 66.67% of the companies in the same industry.
ALMKS has a Return On Equity of -6.68%. This is in the lower half of the industry: ALMKS underperforms 68.12% of its industry peers.
ALMKS has a Return On Invested Capital of 7.61%. This is in the better half of the industry: ALMKS outperforms 69.57% of its industry peers.
Industry RankSector Rank
ROA -1%
ROE -6.68%
ROIC 7.61%
ROA(3y)-2.48%
ROA(5y)-1.44%
ROE(3y)-22.79%
ROE(5y)-9.81%
ROIC(3y)N/A
ROIC(5y)N/A
ALMKS.PA Yearly ROA, ROE, ROICALMKS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 100 150

1.3 Margins

With a Operating Margin value of 1.87%, ALMKS is not doing good in the industry: 60.87% of the companies in the same industry are doing better.
In the last couple of years the Operating Margin of ALMKS has declined.
With a Gross Margin value of 20.49%, ALMKS is not doing good in the industry: 79.71% of the companies in the same industry are doing better.
ALMKS's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 1.87%
PM (TTM) N/A
GM 20.49%
OM growth 3YN/A
OM growth 5Y-6.38%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.38%
GM growth 5Y-5.28%
ALMKS.PA Yearly Profit, Operating, Gross MarginsALMKS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 10 20

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ALMKS is still creating some value.
The number of shares outstanding for ALMKS has been increased compared to 1 year ago.
The number of shares outstanding for ALMKS has been increased compared to 5 years ago.
The debt/assets ratio for ALMKS has been reduced compared to a year ago.
ALMKS.PA Yearly Shares OutstandingALMKS.PA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
ALMKS.PA Yearly Total Debt VS Total AssetsALMKS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of 1.72, we must say that ALMKS is in the distress zone and has some risk of bankruptcy.
ALMKS has a Altman-Z score (1.72) which is comparable to the rest of the industry.
The Debt to FCF ratio of ALMKS is 1126.96, which is on the high side as it means it would take ALMKS, 1126.96 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 1126.96, ALMKS is doing worse than 65.22% of the companies in the same industry.
ALMKS has a Debt/Equity ratio of 0.47. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.47, ALMKS is in the better half of the industry, outperforming 63.77% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 1126.96
Altman-Z 1.72
ROIC/WACC1.11
WACC6.84%
ALMKS.PA Yearly LT Debt VS Equity VS FCFALMKS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 0.75 indicates that ALMKS may have some problems paying its short term obligations.
ALMKS has a Current ratio of 0.75. This is in the lower half of the industry: ALMKS underperforms 75.36% of its industry peers.
ALMKS has a Quick Ratio of 0.75. This is a bad value and indicates that ALMKS is not financially healthy enough and could expect problems in meeting its short term obligations.
ALMKS's Quick ratio of 0.73 is on the low side compared to the rest of the industry. ALMKS is outperformed by 69.57% of its industry peers.
Industry RankSector Rank
Current Ratio 0.75
Quick Ratio 0.73
ALMKS.PA Yearly Current Assets VS Current LiabilitesALMKS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 63.02% over the past year.
The Revenue has grown by 16.03% in the past year. This is quite good.
ALMKS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 51.21% yearly.
EPS 1Y (TTM)63.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-319.11%
Revenue 1Y (TTM)16.03%
Revenue growth 3Y35.32%
Revenue growth 5Y51.21%
Sales Q2Q%21.07%

3.2 Future

Based on estimates for the next years, ALMKS will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.62% on average per year.
Based on estimates for the next years, ALMKS will show a very strong growth in Revenue. The Revenue will grow by 22.10% on average per year.
EPS Next Y-27.27%
EPS Next 2Y11.46%
EPS Next 3Y15.62%
EPS Next 5YN/A
Revenue Next Year33.94%
Revenue Next 2Y25.99%
Revenue Next 3Y22.1%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ALMKS.PA Yearly Revenue VS EstimatesALMKS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
ALMKS.PA Yearly EPS VS EstimatesALMKS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0.1 0.2 0.3 0.4 0.5

1

4. Valuation

4.1 Price/Earnings Ratio

ALMKS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
ALMKS is valuated quite expensively with a Price/Forward Earnings ratio of 33.29.
The rest of the industry has a similar Price/Forward Earnings ratio as ALMKS.
The average S&P500 Price/Forward Earnings ratio is at 36.12. ALMKS is around the same levels.
Industry RankSector Rank
PE N/A
Fwd PE 33.29
ALMKS.PA Price Earnings VS Forward Price EarningsALMKS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

The rest of the industry has a similar Enterprise Value to EBITDA ratio as ALMKS.
Based on the Price/Free Cash Flow ratio, ALMKS is valued a bit more expensive than the industry average as 65.22% of the companies are valued more cheaply.
Industry RankSector Rank
P/FCF 1457.91
EV/EBITDA 9.06
ALMKS.PA Per share dataALMKS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

A more expensive valuation may be justified as ALMKS's earnings are expected to grow with 15.62% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.46%
EPS Next 3Y15.62%

0

5. Dividend

5.1 Amount

ALMKS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

MAKING SCIENCE GROUP SA

EPA:ALMKS (11/26/2025, 7:00:00 PM)

8.15

-0.05 (-0.61%)

Chartmill FA Rating
GICS IndustryGroupMedia & Entertainment
GICS IndustryMedia
Earnings (Last)07-31 2025-07-31
Earnings (Next)N/A N/A
Inst Owners3.56%
Inst Owner ChangeN/A
Ins Owners61.03%
Ins Owner ChangeN/A
Market Cap73.19M
Revenue(TTM)273.55M
Net Income(TTM)-1.72M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-44.19%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 33.29
P/S 0.27
P/FCF 1457.91
P/OCF 224.57
P/B 2.84
P/tB N/A
EV/EBITDA 9.06
EPS(TTM)-0.19
EYN/A
EPS(NY)0.24
Fwd EY3%
FCF(TTM)0.01
FCFY0.07%
OCF(TTM)0.04
OCFY0.45%
SpS30.46
BVpS2.87
TBVpS-4.49
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1%
ROE -6.68%
ROCE 10.35%
ROIC 7.61%
ROICexc 13.76%
ROICexgc N/A
OM 1.87%
PM (TTM) N/A
GM 20.49%
FCFM 0.02%
ROA(3y)-2.48%
ROA(5y)-1.44%
ROE(3y)-22.79%
ROE(5y)-9.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y-6.38%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.38%
GM growth 5Y-5.28%
F-Score6
Asset Turnover1.58
Health
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 1126.96
Debt/EBITDA 1.05
Cap/Depr 4.23%
Cap/Sales 0.1%
Interest Coverage 1.14
Cash Conversion 2.8%
Profit Quality N/A
Current Ratio 0.75
Quick Ratio 0.73
Altman-Z 1.72
F-Score6
WACC6.84%
ROIC/WACC1.11
Cap/Depr(3y)13.72%
Cap/Depr(5y)311.76%
Cap/Sales(3y)0.4%
Cap/Sales(5y)7.85%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-319.11%
EPS Next Y-27.27%
EPS Next 2Y11.46%
EPS Next 3Y15.62%
EPS Next 5YN/A
Revenue 1Y (TTM)16.03%
Revenue growth 3Y35.32%
Revenue growth 5Y51.21%
Sales Q2Q%21.07%
Revenue Next Year33.94%
Revenue Next 2Y25.99%
Revenue Next 3Y22.1%
Revenue Next 5YN/A
EBIT growth 1Y279.3%
EBIT growth 3YN/A
EBIT growth 5Y41.57%
EBIT Next Year200%
EBIT Next 3Y56.86%
EBIT Next 5YN/A
FCF growth 1Y103.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y177.63%
OCF growth 3Y-64.38%
OCF growth 5YN/A

MAKING SCIENCE GROUP SA / ALMKS.PA FAQ

What is the fundamental rating for ALMKS stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALMKS.PA.


What is the valuation status of MAKING SCIENCE GROUP SA (ALMKS.PA) stock?

ChartMill assigns a valuation rating of 1 / 10 to MAKING SCIENCE GROUP SA (ALMKS.PA). This can be considered as Overvalued.


What is the profitability of ALMKS stock?

MAKING SCIENCE GROUP SA (ALMKS.PA) has a profitability rating of 1 / 10.


What is the financial health of MAKING SCIENCE GROUP SA (ALMKS.PA) stock?

The financial health rating of MAKING SCIENCE GROUP SA (ALMKS.PA) is 2 / 10.